lt p gt Neurotrope BioScience, Inc. is a specialty biopharmaceutical company developing new therapeutics for the treatment of rare diseases Orphan diseases and Alzheimers Disease. NTRP has also advanced two other Orphan Disease programs using Bryostatin. We are working with the Ichan School of Medicine at Mt. Sinai Hospital in New York to determine the efficacy of Bryostatin for the treatment of Niemann Pick Disease, Type C. In addition, we are also working with the FRAXA Research Foundation to help find a treatment for Fragile X Syndrome using Bryostatin . NTRP licensed the use of Bryostatin for the treatment of Alzheimers Disease as well as other neurodegenerative diseases from the Blanchette Rockefeller Neuroscience Institute BRNI . To date NTRP has successfully completed a first Phase study in moderate Alzheimers patients. We are now conducting a second Phase study. NTRP has also teamed up with Stanford University to find the next generation Bryostatin Bryologs. lt /p gt
Quote | Neurotrope Inc. (NASDAQ:NTRP)
Last: | $3.30 |
---|---|
Change Percent: | -2.71% |
Open: | $3.41 |
Close: | $3.30 |
High: | $3.41 |
Low: | $3.29 |
Volume: | 3,431 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Neurotrope Inc. (NASDAQ:NTRP)
2024-07-19 17:10:57 ET More on Sigma Additive Solutions Historical earnings data for Sigma Additive Solutions Financial information for Sigma Additive Solutions Read the full article on Seeking Alpha For further details see: NextTrip receives Nasdaq notif...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Message Board Posts | Neurotrope Inc. (NASDAQ:NTRP)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $NTRP News Article - 5 Penny Stocks Gaining Momentum This Week; 1 Up Over 150% | whytestocks | investorshangout | 01/22/2020 3:25:42 PM |
whytestocks: $NTRP News Article - Neurotrope Announces Review of Strategic Alternatives to Maximize | whytestocks | investorshangout | 10/08/2019 1:20:41 PM |
whytestocks: $NTRP News Article - Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chi | whytestocks | investorshangout | 04/01/2019 3:50:41 PM |
whytestocks: $NTRP News Article - Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzh | whytestocks | investorshangout | 03/21/2019 2:05:40 PM |
whytestocks: $NTRP News Article - Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of B | whytestocks | investorshangout | 03/13/2019 7:50:40 PM |
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Dynamic Content-to-Commerce FAST Channel Reinvents Monetization Models SUNRISE, FL / ACCESSWIRE / July 18, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, today announced that it has partnered with OTT ("over-the-top") services...
Allows Consumers to Pay for Accommodations Through Interest-free Installments with Convenient and Flexible Payment Options when Booking Travel Seamless Integration Enables Marketing Opportunities in Social Media Travel Package Campaigns and Direct-to-Consumer Marketing Channels to Drive Sale...